pGAMA-YAP Citations (4)

Originally described in: YAP Induces Human Naive Pluripotency.
Qin H, Hejna M, Liu Y, Percharde M, Wossidlo M, Blouin L, Durruthy-Durruthy J, Wong P, Qi Z, Yu J, Qi LS, Sebastiano V, Song JS, Ramalho-Santos M Cell Rep. 2016 Mar 15;14(10):2301-12. doi: 10.1016/j.celrep.2016.02.036. Epub 2016 Mar 3. PubMed Journal

---

Articles Citing pGAMA-YAP

Articles
A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer. Zhao X, Wang X, Fang L, Lan C, Zheng X, Wang Y, Zhang Y, Han X, Liu S, Cheng K, Zhao Y, Shi J, Guo J, Hao J, Ren H, Nie G. Cancer Lett. 2017 Aug 28;402:61-70. doi: 10.1016/j.canlet.2017.05.015. Epub 2017 May 30. PubMed
Knockdown of HuR represses osteosarcoma cells migration, invasion and stemness through inhibition of YAP activation and increases susceptibility to chemotherapeutic agents. Xu W, Chen C, Xu R, Li Y, Hu R, Li Z, Zhu X. Biomed Pharmacother. 2018 Jun;102:587-593. doi: 10.1016/j.biopha.2018.03.098. Epub 2018 Apr 5. PubMed
YAP-Mediated Repression of HRK Regulates Tumor Growth, Therapy Response, and Survival Under Tumor Environmental Stress in Neuroblastoma. Shim J, Lee JY, Jonus HC, Arnold A, Schnepp RW, Janssen KM, Maximov V, Goldsmith KC. Cancer Res. 2020 Nov 1;80(21):4741-4753. doi: 10.1158/0008-5472.CAN-20-0025. Epub 2020 Sep 8. PubMed
Epigenetic regulator BMI1 promotes alveolar rhabdomyosarcoma proliferation and constitutes a novel therapeutic target. Shields CE, Potlapalli S, Cuya-Smith SM, Chappell SK, Chen D, Martinez D, Pogoriler J, Rathi KS, Patel SA, Oristian KM, Linardic CM, Maris JM, Haynes KA, Schnepp RW. Mol Oncol. 2021 Feb 1. doi: 10.1002/1878-0261.12914. PubMed

If you have published an article using this material, please email us at to have your article added to this page.